Fubotv earnings beat by $0.10, revenue topped estimates
Monday, JMP Securities reiterated its Market Perform rating on Adicet Bio Inc. (NASDAQ:ACET) without setting a new price target. The stock has faced significant headwinds, declining 73% over the past year, with analysts setting price targets between $4 and $8. Adicet Bio, a company specializing in cell therapy with a market capitalization of $43.5 million, shifted focus to autoimmune diseases in 2024, introducing its unique gamma-delta, anti-CD20 CAR-T therapy, ADI-001. The firm began a Phase 1 trial for lupus nephritis (LN) in November 2024 and anticipates sharing preliminary data in the first half of 2025.
Adicet Bio is expanding its research efforts beyond LN, with plans to launch clinical trials for several autoimmune conditions. These include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), and stiff person syndrome (SPS) in the second quarter of 2025. Additionally, the company aims to begin trials for ANCA-associated vasculitis in the second half of the year.
The upcoming fireside chat with JMP Securities is set to cover a range of topics concerning Adicet Bio’s strategic direction. The discussion will include the company’s expectations, potential challenges and milestones that would determine the continuation or cessation of its programs, and how it stands in relation to its competitors in the cell therapy market. For deeper insights into Adicet Bio’s financial health and valuation metrics, InvestingPro subscribers can access comprehensive analysis through the Pro Research Report, which covers over 1,400 US stocks.
Adicet Bio’s pivot into the autoimmune space and its comprehensive pipeline of trials for various diseases represent significant steps for the company. The medical community and investors will be looking forward to the data update from the ongoing Phase 1 trial, as well as the insights from the fireside chat to better understand the company’s trajectory and potential impact on the treatment of autoimmune diseases.
In other recent news, Adicet Bio has made notable advancements in its clinical trials and strategic leadership. The company is actively enrolling patients in its Phase 1 trial for ADI-001, targeting lupus nephritis, with preliminary results expected in the first half of 2025. Additionally, Adicet Bio has received Fast Track Designation from the FDA for ADI-001, which is being evaluated for systemic sclerosis and other autoimmune diseases. The company has also appointed Michael Grissinger to its Board of Directors, bringing over forty years of pharmaceutical industry experience to bolster its strategic growth. Meanwhile, Adicet Bio faces a challenge with Nasdaq, as it has been notified of non-compliance with the minimum bid price requirement. The company has until October 6, 2025, to rectify this issue to maintain its listing. H.C. Wainwright has maintained a Neutral rating on Adicet Bio, reflecting cautious optimism about its product development. Adicet Bio’s ongoing efforts in clinical trials and strategic initiatives are being closely watched by investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.